<DOC>
	<DOC>NCT01529229</DOC>
	<brief_summary>The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis.</brief_summary>
	<brief_title>Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment</brief_title>
	<detailed_description>- double-blind, non-inferiority, prospective, parallel group trial. - Experiment duration: 07 days. - 02 visits (days 0 and 7). - Efficacy will be evaluated for persistent allergic rhinitis based on nasal symptoms score - Adverse events evaluation.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Dexchlorpheniramine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Consent of the patient or legal guardian; Clinical diagnosis of moderate severe persistent allergic rhinitis according to the classification of ARIA (Allergic Rhinitis and Its Impact on Asthma); Children aged between 2 and 11 years and 11 months (up to 30 kg); Presence of nasal symptoms score greater than or equal to 5 (scale 0 to 12)in the last week; Evidence of sensitization to aeroallergens in examination (immediate skin tests or serum specific IgE) in the 12 months prior to inclusion. Participation in clinical trial in 30 days prior to study entry; Patients receiving immunotherapy; Patients with history of hypersensitivity to desloratadine or prednisolone or with corticosteroids use contraindications ; Patients with any clinically significant disease other than allergic rhinitis, including hematopoietic, cardiovascular, renal, neurological, psychiatric or autoimmune disorders; Patients on treatment with monoamine oxidase inhibitors (MAOIs); Patients who were in use of oral antihistamines or decongestants in the past 15 days; Patients who were treated with systemic corticosteroids in the last month; Patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and nasal anatomic abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>